

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

### Complete if Known

Application Number	09/462,682
Filing Date	April 28, 2000
First Named Inventor	FitzGerald, David
Group Art Unit	1645
Examiner Name	Portner, Virginia
Attorney Docket Number	015280-310100US

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
VAP	1	09/462,713		Fitzgerald		

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

Examiner  
Signature

Date  
Considered


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1347082 v1

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**


(use as many sheets as necessary)

**Complete if Known**

Application Number	09/462,682
Filing Date	April 28, 2000
First Named Inventor	FitzGerald, David
Group Art Unit	1645
Examiner Name	Portner, Virginia
Attorney Docket Number	015280-310100US

Sheet 2 of 2

## **OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	2	CHOE, et al. Cancer Res "B3(Fab)-PE38M: a recombinant immunotoxin in which a mutant form of <i>Pseudomonas</i> exotoxin is fused to the Fab fragment of monoclonal antibody B3" 1994 July Vol 54, Issue 13 pp 3460-7	
	3	KREITMAN, et al. Bioconjug Chem "Properties of Chimeric Toxins with Two Recognition Domains: Interleukin 6 and transforming growth factor $\alpha$ at different locations in <i>Pseudomonas</i> Exotoxin" Vol 3, Issue 1 (1992) pp 3-8	
	4	KUAN, et al. J Biol Chem "Pseudomonas Exotoxin A Mutants. Replacement of Surface Exposed Residues in Domain II with Cysteine Residues that can be Modified with Polyethylene Glycol in a Site-Specific Manner" 1994 March Vol. 269, Issue 10 pp 7610-16	
	5	MANSFIELD, et al. Bioconjug Chem "Characterization of RFB4- <i>Pseudomonas</i> Exotoxin A Immunotoxins Targeted to CD22 on B-cell Malignancies" Vol. 7, Issue 5, pp 557-63 (1996)	
	6	THEUER, et al. Cancer Res "Immunotoxins made with a recombinant form of <i>Pseudomonas</i> exotoxin A that do not require proteolysis for activity" Volume 53, Issue 2, pp. 340-347 (Jan. 1993)	
	7	KUAN, et al. Proc. Natl. Acad. Sci USA "Improved antitumor activity of a recombinant anti-Lewis immunotoxin not requiring proteolytic activation" vol 93, pp 974-978 (Feb. 1996)	
	8		
	9		

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1347082 v1